New anchor investor Elevat3 Capital joins tiakis Biotech AG.
October 2021 –
tiakis Biotech AG (formerly Proteo Biotech AG) has announced that the Company has successfully completed a series-A financing round to support its ongoing innovative development programs.
Elevat3 Capital, the European investment arm of Apeiron Investment Group, is joining tiakis as its anchor investor to explore and develop the full potential of its investigational medical product Tiprelestat.
tiakis welcomes Elevat3 and is looking forward to strengthening this partnership in the years to come.
tiakis BIOTECH AG
phone: +49 431 8888-462
fax: +49 431 8888-463